Full-Time

Associate Director, Campaign Orchestration

Patient, EMD Business Partner

Posted on 9/10/2026

Jazz Pharmaceuticals

Jazz Pharmaceuticals

1,001-5,000 employees

Biopharmaceuticals focused on neuroscience and oncology

Compensation Overview

$156k - $234k/yr

Pennsylvania, USA

Remote

Remote within Pennsylvania, with 20–30% travel required.

Bachelor's, Master's, MBA

Category
Growth & Marketing (1)

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Requirements
  • Expertise in omnichannel patient campaign orchestration, including designing and executing coordinated engagement plans for the epilepsy and movement disorders franchise.
  • Ability to translate patient and caregiver strategy into practical orchestration requirements, workstreams, and execution plans within a matrixed enterprise environment.
  • Proficiency in using patient engagement, performance, and experience data to inform orchestration decisions and continuously refine patient journeys.
  • Experience leveraging enterprise customer experience platforms, data inputs, and global capability products to enable scalable, repeatable patient execution and reduce manual coordination.
  • Demonstrated ability to independently own complex, cross-functional patient orchestration initiatives from strategy through execution.
  • Bachelor’s degree in business, healthcare, technology, or a related field.
  • 8+ years of experience in omnichannel campaign orchestration, campaign planning, or related customer experience capabilities within a pharmaceutical organization.
  • Ability to view problems, opportunities, and decisions from customer, healthcare professional, patient, market, or external stakeholder perspectives and act on insights and external best practices.
  • Ability to work fluidly across teams and reporting lines, coordinate shared work, and ensure progress when accountability is distributed.
  • Ability to understand upstream and downstream effects across the organization and identify patterns and interdependencies.
  • Ability to improve processes and products through reflection and iteration and generate new approaches when constraints exist.
  • Ability to understand how value is created financially, operationally, and for customers, and use that understanding to make decisions.
  • Ability to take responsibility for outcomes and drive work forward with urgency, clarity, and focus on impact.
  • Ability to explore user needs, emerging technologies, and new ways of working to improve capability and innovation.
  • Ability to adapt quickly to change and help others navigate dynamic environments.
  • Ability to prioritize enterprise value, break down silos, and build trust-based partnerships across teams.
  • Ability to set ambitious goals, challenge assumptions, and drive measurable business impact.
  • Ability to navigate ambiguity using sound judgment, data, and user insights.
  • Ability to communicate clearly, simplify complexity, align stakeholders, and ensure shared understanding of priorities and outcomes.
Responsibilities
  • Apply understanding of epilepsy and movement disorders patient needs, behaviors, care pathways, sites of care, and patient and caregiver dynamics to inform orchestration decisions.
  • Shape execution of cross-functional engagement strategy for the epilepsy and movement disorders franchise by influencing orchestration principles, resolving tradeoffs, and ensuring patient strategies are executed cohesively.
  • Orchestrate coordinated omnichannel patient campaigns that translate franchise strategies into integrated engagement plans aligned to patient and caregiver journeys.
  • Apply next-best-action frameworks and orchestration logic to sequence and prioritize patient and caregiver touchpoints across channels.
  • Own delivery of patient orchestration needs by translating strategy into sequenced cross-channel engagement.
  • Define and oversee patient-focused media strategy for the epilepsy and movement disorders franchise, including channel mix, audience targeting, and campaign planning.
  • Drive patient media activation and performance, including search, cross-channel buying, and tentpole campaign coordination.
  • Partner with Customer Analytics & Insights and Customer Orchestration teams to track and improve media performance using measures and tools such as MMA, social listening, and IQVIA.
  • Leverage global capabilities, standards, and tools to enable scalable and consistent patient campaign execution and reduce duplication.
  • Use performance, engagement, and patient experience insights to refine sequencing, identify risks, and improve effectiveness across integrated campaigns.
  • Track and manage key performance indicators and escalate risks and issues to support patient and business outcomes.
  • Provide structured feedback to strengthen enterprise customer experience and patient orchestration standards based on learnings from the epilepsy and movement disorders franchise.
  • Partner with brand, medical, analytics, field engagement, market access, patient support, and enterprise customer experience teams to align patient priorities, manage interdependencies, and enable consistent delivery.
  • Share patient insights, risks, and learnings with customer experience peers and leadership to drive alignment and continuous improvement in patient engagement approaches.
  • Travel 20–30% as required.
Desired Qualifications
  • Advanced degree, such as an MBA or relevant graduate degree.
  • Experience in healthcare, pharmaceutical, or other highly regulated industries.
  • Experience working in rare disease or specialty brands, with a strong understanding of unique stakeholder dynamics.

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Second-quarter 2026 revenue reached $1.21 billion, and full-year guidance rose to $4.60-$4.75 billion.
  • Ziihera approval on August 25, 2026 opens a $3 billion-$5 billion peak-sales opportunity.
  • Zepzelca and Xywav posted strong 2026 growth, validating Jazz's oncology and sleep franchises.

What critics are saying

  • Lupin, Teva, and Tris challenge Xywav and Xyrem, threatening 2027-2033 economics.
  • Granules settled in March 2026 with launch rights under confidential terms, pressuring Xywav pricing.
  • Jazz took on Actio for $820 million upfront; ABS-1230 still faces clinical and regulatory failure.

What makes Jazz Pharmaceuticals unique

  • Xywav owns narcolepsy and idiopathic hypersomnia through FDA orphan exclusivity until July 2027.
  • Epidiolex gives Jazz rare epilepsy scale, with durable U.S. brand recognition since 2021 GW acquisition.
  • Ziihera launch on August 25, 2026 expands Jazz into HER2-positive gastroesophageal cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

0%
StockTitan
Aug 27th, 2026
Jazz Pharmaceuticals prices upsized $1.1B exchangeable notes offering with $225M share repurchase

Jazz Pharmaceuticals has priced an upsized $1.1 billion private offering of 1.875% exchangeable senior notes due 2032, up from the previously announced $1.0 billion. The offering, conducted through its wholly-owned subsidiary Jazz Investments I Limited, is expected to close on 31 August 2026. The notes will mature on 15 September 2032 and are exchangeable at an initial rate of 2.8150 ordinary shares per $1,000 principal amount, equivalent to an exchange price of approximately $355.24 per share. This represents a 42.5% premium above the last reported sale price on 26 August 2026. The company will use net proceeds of approximately $1,079 million for general corporate purposes. Concurrently, Jazz Pharmaceuticals agreed to repurchase approximately $225 million of its ordinary shares from note purchasers at $249.29 per share, using existing cash on hand.

Yahoo Finance
Aug 26th, 2026
Jazz Pharmaceuticals launches Ziihera for HER2-positive cancer with $3B–$5B peak sales outlook

Jazz Pharmaceuticals has launched Ziihera in the US following FDA approval for first-line treatment of HER2-positive, unresectable or metastatic gastroesophageal adenocarcinoma. The drug can be used with tislelizumab and chemotherapy, or with chemotherapy alone for certain patients. In the Phase III HERIZON-GEA-01 trial, Ziihera-based regimens reduced the risk of disease progression or death by 35%. The triplet regimen extended median overall survival to 26.4 months, a 28% reduction in death risk versus trastuzumab. Jazz estimates the US addressable market at 3,000–4,000 patients annually and raised Ziihera's peak sales outlook to $3 billion–$5 billion. The company plans to leverage existing commercial infrastructure whilst pursuing additional cancer indications and international regulatory filings.

Yahoo Finance
Aug 11th, 2026
Jazz Pharmaceuticals Q2 revenue beats estimates at $1.21B, ups guidance to $4.68B

Jazz Pharmaceuticals reported a strong second quarter with revenue of $1.21 billion, beating analyst estimates of $1.12 billion and representing 15.5% year-on-year growth. The company raised its full-year revenue guidance to $4.68 billion from $4.38 billion. CEO Renée Galá attributed the performance to strong demand for flagship products like Xywav and Epidiolex, alongside accelerating uptake of new oncology therapies. Operating margin improved to 20.5%, up from negative 65.6% in the prior year quarter. However, adjusted earnings per share of $5.71 missed analyst expectations of $6.18. During the earnings call, analysts focused on Epidiolex's growth drivers, Xywav's sustainability amid potential generic competition, and zanidatamab's upcoming approval prospects.

Yahoo Finance
Aug 11th, 2026
Jazz Pharma raises 2026 guidance on record Q2 revenue of $1.2B, up 16%

Jazz Pharmaceuticals reported record second quarter revenue of $1.2 billion, representing 16% year-over-year growth. The company raised its full-year revenue guidance based on strong first-half performance. Chief executive officer Renée Galá attributed the results to execution across the company's diversified portfolio and sustained demand for its commercial products. The company is preparing to launch zanidatamab, with a PDUFA date of 25 August for treatment of first-line HER2-positive metastatic gastroesophageal adenocarcinoma. The earnings call included updates from senior leadership, including chief commercial officer Samantha Pearce, global head of research and development Robert Iannone, and chief financial officer Philip Johnson. Jazz Pharmaceuticals highlighted progress on its long-term value creation priorities whilst maintaining focus on current commercial operations.

Yahoo Finance
Aug 10th, 2026
Jazz Pharmaceuticals to acquire Actio Biosciences for $820M upfront, adding KCNT1+ epilepsy therapy

Jazz Pharmaceuticals has agreed to acquire Actio Biosciences for $820 million upfront and up to $500 million in contingent payments. The deal adds ABS-1230, a clinical-stage precision therapy for KCNT1+ epilepsy, to Jazz's rare epilepsy portfolio. KCNT1+ epilepsy is a rare genetic condition affecting approximately 2,500 patients in the United States. Patients typically experience dozens to hundreds of seizures daily that resist standard medications. Around 80% of cases begin in infancy, with many children unable to reach basic developmental milestones. There are currently no FDA-approved therapies for KCNT1+ epilepsy. ABS-1230 recently showed meaningful seizure reductions in an early clinical trial. The ongoing Phase 1b/2a KYRON trial is designed as the registrational study supporting US new drug application submission.